Exclusive Summary

• This product, as a nationally clinically essential and easily short-supplied medicine, addresses significant unmet needs and offers global market opportunities.
• Being the first to pass bioequivalence assessment with self-produced raw materials, the product ensures reliable quality and strong cost control, enhancing its international competitiveness.
• As a basic medicine covered by national health insurance, it guarantees good accessibility and payment, facilitating market penetration.
• It possesses clear clinical value in critical care areas like pediatric pulmonary hypertension, aligning with WHO essential medicines and most guideline recommendations.
• The market is under-penetrated with relatively low competition, indicating untapped market potential.

Asset Materials

Contact Us for Full Materials